The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Dragonfly Therapeutics; Fidia Farmaceutici S. p. A.; Merck; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech
 
Johannes Alfred Witjes
Honoraria - Astellas Pharma; Beigene; Ipsen; Nucleix
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD; Nucleix; Oncodiag; Sanofi/Aventis
 
Jürgen Gschwend
Honoraria - Bayer Schering Pharma; Janssen-Cilag
Consulting or Advisory Role - Bayer Schering Pharma; Janssen-Cilag
 
Michael Schenker
Research Funding - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Pfizer/EMD Serono; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Begoña P. Valderrama
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Pierre Fabre; Roche
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; EUSA Pharma; Ipsen; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Ipsen; MSD Oncology; Pfizer; Roche
 
Yoshihiko Tomita
Research Funding - Astellas Pharma (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
Other Relationship - Astellas Pharma; Bristol-Myers Squibb; Ono Pharmaceutical; Pfizer
 
Aristotelis Bamias
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Debiopharm Group; MSD; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Pfizer; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; Pfizer; Roche
 
Thierry Lebret
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Ipsen
Travel, Accommodations, Expenses - Ipsen; Novartis; Pfizer
Other Relationship - Astellas Pharma
 
Shahrokh Shariat
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Lilly; MSD; Olympus; Pfizer; Pierre Fabre; Richard Wolf; Roche; Sanochemia; Sanofi; Takeda; UroGen pharma
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Janssen; MSD; Olympus; Pfizer; Pierre Fabre; Richard Wolf; Roche; Sanochemia; Sanofi; Takeda; UroGen pharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Janssen; Lilly; Movember Foundation; MSD; Olympus; Pfizer; Pierre Fabre; Richard Wolf; Sanochemia; Sanofi; Takeda; UroGen pharma
 
Se Hoon Park
Consulting or Advisory Role - Janssen; Lilly
Research Funding - Ono Pharmaceutical
 
Dingwei Ye
No Relationships to Disclose
 
Mads Agerbaek
No Relationships to Disclose
 
Sandra Collette
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Keziban Unsal-Kacmaz
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Dimitrios Zardavas
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Henry B. Koon
No Relationships to Disclose
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792